NEFA (drug)
Appearance
From Wikipedia, the free encyclopedia
Chemical compound
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H19N |
Molar mass | 213.324 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
NEFA is a moderate affinity NMDA antagonist (IC50 = 0.51 μM). It is a structural analog of phencyclidine.[1] It was first synthesized by a team at Parke-Davis in the late 1950s.[2]
References
[edit]- ^ Dilmore JG, Johnson JW (1998). "Open channel block and alteration of N-methyl-D-aspartic acid receptor gating by an analog of phencyclidine". Biophysical Journal. 75 (4): 1801–16. Bibcode:1998BpJ....75.1801D. doi:10.1016/S0006-3495(98)77622-2. PMC 1299852. PMID 9746522.
- ^ GB Patent 893920 - Polycyclic amino compounds and methods for their production
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
---|---|
KARTooltip Kainate receptor |
|
NMDARTooltip N-Methyl-D-aspartate receptor |
|
This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Infobox drug articles with non-default infobox title
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs missing an ATC code
- Drugs with no legal status
- Drugboxes which contain changes to watched fields
- All stub articles